322 related articles for article (PubMed ID: 36500212)
1. Current Challenges in Small Molecule Proximity-Inducing Compound Development for Targeted Protein Degradation Using the Ubiquitin Proteasomal System.
Radhakrishnan S; Hoff O; Muellner MK
Molecules; 2022 Nov; 27(23):. PubMed ID: 36500212
[TBL] [Abstract][Full Text] [Related]
2. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.
Kannt A; Đikić I
Cell Chem Biol; 2021 Jul; 28(7):1014-1031. PubMed ID: 33945791
[TBL] [Abstract][Full Text] [Related]
3. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
[TBL] [Abstract][Full Text] [Related]
4. Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators.
Rothweiler EM; Brennan PE; Huber KVM
Biol Chem; 2022 Mar; 403(4):391-402. PubMed ID: 35191283
[TBL] [Abstract][Full Text] [Related]
5. Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory.
Cowan AD; Ciulli A
Annu Rev Biochem; 2022 Jun; 91():295-319. PubMed ID: 35320687
[TBL] [Abstract][Full Text] [Related]
6. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.
Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK
ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647
[TBL] [Abstract][Full Text] [Related]
7. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
8. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
Diehl CJ; Ciulli A
Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
[TBL] [Abstract][Full Text] [Related]
9. Targeted Degradation of 53BP1 Using Ubiquitin Variant Induced Proximity.
Aminu B; Fux J; Mallette E; Petersen N; Zhang W
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454069
[TBL] [Abstract][Full Text] [Related]
10. Targeted protein degradation and the enzymology of degraders.
Fisher SL; Phillips AJ
Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
[TBL] [Abstract][Full Text] [Related]
11. Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.
Guharoy M; Bhowmick P; Tompa P
J Biol Chem; 2016 Mar; 291(13):6723-31. PubMed ID: 26851277
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on the development of first-in-class protein degraders.
Rambacher KM; Calabrese MF; Yamaguchi M
Future Med Chem; 2021 Jul; 13(14):1203-1226. PubMed ID: 34015962
[TBL] [Abstract][Full Text] [Related]
13. Targeted protein degradation via intramolecular bivalent glues.
Hsia O; Hinterndorfer M; Cowan AD; Iso K; Ishida T; Sundaramoorthy R; Nakasone MA; Imrichova H; Schätz C; Rukavina A; Husnjak K; Wegner M; Correa-Sáez A; Craigon C; Casement R; Maniaci C; Testa A; Kaulich M; Dikic I; Winter GE; Ciulli A
Nature; 2024 Mar; 627(8002):204-211. PubMed ID: 38383787
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
15. The PROTAC technology in drug development.
Zou Y; Ma D; Wang Y
Cell Biochem Funct; 2019 Jan; 37(1):21-30. PubMed ID: 30604499
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
[TBL] [Abstract][Full Text] [Related]
17. The aptamer-based RNA-PROTAC.
Xu Y; Yuan Y; Fu DQ; Fu Y; Zhou S; Yang WT; Wang XY; Li GX; Dong J; Du F; Huang X; Wang QW; Tang Z
Bioorg Med Chem; 2023 May; 86():117299. PubMed ID: 37137271
[TBL] [Abstract][Full Text] [Related]
18. Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.
Nguyen HC; Wang W; Xiong Y
Subcell Biochem; 2017; 83():323-347. PubMed ID: 28271482
[TBL] [Abstract][Full Text] [Related]
19. PROTACs: past, present and future.
Li K; Crews CM
Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
[TBL] [Abstract][Full Text] [Related]
20. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
Belcher BP; Ward CC; Nomura DK
Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
